EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A heterodimer of hemoglobin identifies theranostic targets on brain‐metastasizing melanoma cells

Maharrish Chelladurai, Orit Sagi-Assif, Shlomit Ben-Menachem, Tsipi Meshel, Metsada Pasmanik-Chor, Sivan Izraely, Dave S B Hoon iD, Isaac P Witz iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Maharrish Chelladurai und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms, Hemoglobins. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer microenvironments encompass both cancer‐promoting and cancer‐restraining factors. If these factors cancel each other, cancer dormancy may ensue. In search of microenvironmental factors that keep dormant lung‐metastasizing neuroblastoma cells and brain‐metastasizing melanoma cells (BMMC) in check, we identified the beta subunit of hemoglobin and a heterodimer of alpha and beta chains of hemoglobin (α/β dimer) in the lung and brain microenvironments, respectively, as anti‐metastatic factors. A previous study demonstrated that the α/β dimer triggers programmed cell death of BMMC and downregulates the expression of BRD4, GAB2, and IRS2 proteins, which perform essential functions in tumorigenesis and progression. The working hypothesis of the present study is that in addition to its tumoricidal function, the α/β dimer serves as a pathfinder for the identification of therapy targets for BMMC. We, therefore, employed small‐molecule inhibitors of Bromodomain‐containing protein 4 (BRD4), GRB2‐associated‐binding protein 2 (GAB2), and Insulin receptor substrate 2 (IRS2) as potential anti‐BMMC agents. A combination of sub‐lethal concentrations of BRD4 and IRS2 inhibitors synergistically arrested BMMC at the subG1 phase of the cell cycle and killed more than 70% of BMMCs. The BRD4/IRS2 inhibitor cocktail (designated hereafter as BRIRi) moderated the malignancy of BMMC lines from four different human melanomas. Preliminary results suggest that the BRIRi modulated “cold” BMMC to “hot” ones. Among the top enriched functions of differentially expressed genes identified by RNAseq of BRIRi‐treated versus control BMMC, TNF and apoptotic signaling pathways were observed. We propose that co‐targeting BRD4 and IRS2 offers a promising approach for treating BMMC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaBrain NeoplasmsHemoglobinsHumansTranscription FactorsCell Cycle ProteinsCell Line, TumorInsulin Receptor Substrate ProteinsAdaptor Proteins, Signal TransducingTumor MicroenvironmentAnimalsApoptosisGene Expression Regulation, NeoplasticNuclear ProteinsProtein MultimerizationBromodomain Containing Proteins

Stichwörter der Autor:innen

JQ1 (BRD4 inhibitor)NT157 (IRS2 inhibitor)melanomamelanoma brain metastasistumor microenvironment

Substanzen

Transcription FactorsCell Cycle ProteinsBRD4 protein, humanInsulin Receptor Substrate ProteinsHemoglobinsIRS2 protein, humanAdaptor Proteins, Signal TransducingNuclear ProteinsBromodomain Containing Proteins

Autor:innen und Institutionen

  • The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel.
  • Bioinformatics Unit, The George S. Wise Faculty of Life Science, Tel Aviv University, Tel-Aviv, Israel.
  • Department of Translational Molecular Medicine and Sequencing Center, Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA.

ORCID-Profile: Dave S B Hoon, Isaac P Witz

Zitieren

APA

Chelladurai, M., Sagi-Assif, O., Ben-Menachem, S., Meshel, T., Pasmanik-Chor, M., Izraely, S., Hoon, D. S. B., & Witz, I. P. (2025). A heterodimer of hemoglobin identifies theranostic targets on brain‐metastasizing melanoma cells. International Journal of Cancer. https://doi.org/10.1002/ijc.35458

Vancouver

Chelladurai M, Sagi-Assif O, Ben-Menachem S, Meshel T, Pasmanik-Chor M, Izraely S, et al. A heterodimer of hemoglobin identifies theranostic targets on brain‐metastasizing melanoma cells. International Journal of Cancer. 2025. doi:10.1002/ijc.35458

BibTeX
@article{Chelladurai2025,
  author = {Chelladurai, Maharrish and Sagi-Assif, Orit and Ben-Menachem, Shlomit and Meshel, Tsipi and Pasmanik-Chor, Metsada and Izraely, Sivan and Hoon, Dave S B and Witz, Isaac P},
  title = {A heterodimer of hemoglobin identifies theranostic targets on brain‐metastasizing melanoma cells},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35458}
}
Kostenlos starten →